Publications may either be freely available or require a fee to view (or access) on the journal’s website.
Chronic Hepatitis C virus (HCV) can lead to liver failure, liver cancer, and death. In 2013, the Food and Drug Administration approved a new type of HCV treatment called direct-acting antiviral medicine. The PCORI-funded study examined short- and long-term effects on patients treated by this newer medicine. As reported in Liver International, three months after completing treatment, patients reported less fatigue, better sleep quality, and better ability to do daily tasks than before treatment. These improvements held over 12 months.